Condition: Actinic Keratosis (AK) · Sponsor: Avant Health LLC
The goal of this observational study is to learn about the effectiveness of tirbanibulin among adult subjects with actinic keratosis (AK) lesions in the face. The main question it aim to answer is: How does tirbanibulin improve subject's overall appearance of the skin, improve how patient's skin looks, and improve patient's skin texture, in a 57-day observation period. Participants already taking tirbanibulin as part of their regular medical care for AK will answer online survey questions at the beginning of the study and at Day 57.
This description comes directly from the study's public registry record.
Siva Narayanan, PhD, MPhil, MHS, MSc · 301-799-AVANT · info@avant-health.com
Always discuss trial participation with your own doctor first.
| Ablon Skin Institute and Research Center | Manhattan Beach, California, United States | Recruiting |
| Dermatology & Laser Center of Charleston | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07657988